Hypertension
Hypertension
Search
Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD
OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)
EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease
EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice 1,2,3 Phase III trial also demonstrated a 14% statistically significant reduction
France
France
Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project
Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project
Diabetes
Diabetes
Scleroderma
Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease
Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease
Human Health Partnering
Human Health Partnering
Health Canada approves first treatment option for generalized pustular psoriasis flares in adults
- Generalized pustular psoriasis differs significantly from plaque psoriasis in both its disease mechanism and severity.1 - In the EFFISAYIL®-1 trial, over half of the SPEVIGO® (spesolimab)-treated patients were free of pustules, one week after receiving
Science Stories
Science and Innovation - Human Health Innovation - Science Stories
Equine asthma: Recognizing and managing respiratory issues in horses
Equine asthma: Recognizing and managing respiratory issues in horses
Science Focus
Science and Innovation - Human Health Innovation - Science Focus
Vaccines
Science and Innovation - Animal Health Innovation - Vaccines
Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population
Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population
The Research Process
Science and Innovation - Animal Health Innovation - Parasiticides
Lung Cancer
Lung Cancer
Livestock
Livestock
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Boehringer Ingelheim increases commitments to sustainable development
Boehringer Ingelheim increases commitments to sustainable development
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer
Parasiticides
Science and Innovation - Animal Health Innovation - Parasiticides
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients